Physician profile
Chandra Krishnasastry
NPI 1194794172
$4,398.92
in general payments reported to CMS, 2019-2025
12 companies · $99.29 in 2025
The $99.29 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,749 · 2020: $31.14 · 2021: $163 · 2022: $36.55 · 2023: $265 · 2024: $55.03 · 2025: $99.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,545.34 | 2019 | |
| Abbvie INC. | $178.65 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $156.57 | 2023 | Ingrezza |
| Allergan, INC. | $120.21 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $114.77 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $93.56 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.89 | 2024-2025 | Caplyta |
| Alkermes, INC. | $44.19 | 2022-2024 | Aristada, Lybalvi |
| Indivior INC. | $31.10 | 2022-2023 | Perseris |
| Lilly USA, LLC | $22.43 | 2021 | |
| Bioxcel Therapeutics, INC. | $21.12 | 2023 | Igalmi |
| Noven Therapeutics, LLC | $17.09 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Krishnasastry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.